Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-10-2015 | Guidelines

¹⁸F-NaF PET/CT: EANM procedure guidelines for bone imaging

Authors: M. Beheshti, F. M. Mottaghy, F. Payche, F. F. F. Behrendt, T. Van den Wyngaert, I. Fogelman, K. Strobel, M. Celli, S. Fanti, F. Giammarile, B. Krause, W. Langsteger

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2015

Abstract

The aim of this guideline is to provide minimum standards for the performance and interpretation of ¹⁸F-NaF PET/CT scans. Standard acquisition and interpretation of nuclear imaging modalities will help to provide consistent data acquisition and numeric values between different platforms and institutes and to promote the use of PET/CT modality as an established diagnostic modality in routine clinical practice. This will also improve the value of scientific work and its contribution to evidence-based medicine.

Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med. 1962;3:332–4.PubMed

Czernin J, Satyamurthy N, Schiepers C. Molecular mechanisms of bone 18F-NaF deposition. J Nucl Med. 51:1826–9. doi: 10.2967/jnumed.110.077933.

Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49:68–78. doi:10.2967/jnumed.106.037200.CrossRefPubMed

Beheshti M, Langsteger W, Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009;39:396–407. doi:10.1053/j.semnuclmed.2009.05.003.CrossRefPubMed

Ben-Haim S, Israel O. Breast cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009;39:408–15. doi:10.1053/j.semnuclmed.2009.05.002.CrossRefPubMed

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. doi:10.1007/s00259-014-2961-x.CrossRefPubMed

Segall G, Delbeke D, Stabin MG, Even-Sapir E, Fair J, Sajdak R, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med. 51:1813–20. doi: 10.2967/jnumed.110.082263.

Hawkins RA, Choi Y, Huang SC, Hoh CK, Dahlbom M, Schiepers C, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992;33:633–42.PubMed

Moore AE, Blake GM, Taylor KA, Ruff VA, Rana AE, Wan X, et al. Changes observed in radionuclide bone scans during and after teriparatide treatment for osteoporosis. Eur J Nucl Med Mol Imaging. 39:326-36. doi:10.1007/s00259-011-1974-y.

10.

Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31:28–49.CrossRefPubMed

11.

Messa C, Goodman WG, Hoh CK, Choi Y, Nissenson AR, Salusky IB, et al. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metab. 1993;77:949–55.PubMed

12.

Piert M, Zittel TT, Becker GA, Jahn M, Stahlschmidt A, Maier G, et al. Assessment of porcine bone metabolism by dynamic. J Nucl Med. 2001;42:1091–100.PubMed

13.

Fogelman I. Skeletal uptake of diphosphonate: a review. Eur J Nucl Med. 1980;5:473–6.PubMed

14.

Wootton RCD. The single-passage extraction of 18F in rabbit bone. Clin Phys Physiol Meas. 1966;7:333–43.CrossRef

15.

Weber DA, Greenberg EJ, Dimich A, Kenny PJ, Rothschild EO, Myers WP, et al. Kinetics of radionuclides used for bone studies. J Nucl Med. 1969;10:8–17.PubMed

16.

Blake GM, Moore AE, Fogelman I. Quantitative studies of bone using (99m)Tc-methylene diphosphonate skeletal plasma clearance. Semin Nucl Med. 2009;39:369–79. doi:10.1053/j.semnuclmed.2009.05.001.CrossRefPubMed

17.

Blake GM, Siddique M, Frost ML, Moore AE, Fogelman I. Imaging of site specific bone turnover in osteoporosis using positron emission tomography. Curr Osteoporos Rep. 2014;12:475–85. doi:10.1007/s11914-014-0231-2.CrossRefPubMed

18.

Blake GM, Frost ML, Fogelman I. Quantitative radionuclide studies of bone. J Nucl Med. 2009;50:1747–50. doi:10.2967/jnumed.109.063263.CrossRefPubMed

19.

Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for Positron Emission Tomography (NaF-18) to Identify Bone Metastasis of Cancer. 2010;220.6.19.

20.

NOPR. National Oncologic PET Registry. 2012.

21.

Hillner BE, Siegel BA, Hanna L, Duan F, Shields AF, Quinn B, et al. Impact of 18F-Fluoride PET on intended management of patients with cancers other than prostate cancer: results from the national oncologic PET registry. J Nucl Med. 2014;55:1054–61. doi:10.2967/jnumed.113.135475.CrossRefPubMed

22.

Hillner BE, Siegel BA, Hanna L, Duan F, Shields AF, Coleman RE. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry. J Nucl Med. 2014;55:574–81. doi:10.2967/jnumed.113.130005.CrossRefPubMed

23.

Savelli G, Maffioli L, Maccauro M, De Deckere E, Bombardieri E. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med. 2001;45:27–37.PubMed

24.

Chan SC, Wang HM, Ng SH, Hsu CL, Lin YJ, Lin CY, et al. Utility of 18F-fluoride PET/CT and 18F-FDG PET/CT in the detection of bony metastases in heightened-risk head and neck cancer patients. J Nucl Med. 2012;53:1730–5. doi:10.2967/jnumed.112.104893.CrossRefPubMed

25.

Horger M, Bares R. The role of single-photon emission computed tomography/computed tomography in benign and malignant bone disease. Semin Nucl Med. 2006;36:286–94. doi:10.1053/j.semnuclmed.2006.05.001.CrossRefPubMed

26.

Even SE. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005;46:1356–67.

27.

Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80:1588–94. doi:10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G.

28.

Han LJ, Au-Yong TK, Tong WC, Chu KS, Szeto LT, Wong CP. Comparison of bone single-photon emission tomography and planar imaging in the detection of vertebral metastases in patients with back pain. Eur J Nucl Med. 1998;25:635–8.CrossRefPubMed

29.

Kosuda S, Kaji T, Yokoyama H, Yokokawa T, Katayama M, Iriye T, et al. Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI? J Nucl Med. 1996;37:975–8.PubMed

30.

Savelli G, Chiti A, Grasselli G, Maccauro M, Rodari M, Bombardieri E. The role of bone SPET study in diagnosis of single vertebral metastases. Anticancer Res. 2000;20:1115–20.PubMed

31.

Even-Sapir E, Martin RH, Barnes DC, Pringle CR, Iles SE, Mitchell MJ. Role of SPECT in differentiating malignant from benign lesions in the lower thoracic and lumbar vertebrae. Radiology. 1993;187:193–8.CrossRefPubMed

32.

Gates GF. SPECT bone scanning of the spine. Semin Nucl Med. 1998;28:78–94.CrossRefPubMed

33.

Jacobson AF, Fogelman I. Bone scanning in clinical oncology: does it have a future? Eur J Nucl Med. 1998;25:1219–23.CrossRefPubMed

34.

Uematsu T, Yuen S, Yukisawa S, Aramaki T, Morimoto N, Endo M, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol. 2005;184:1266–73.CrossRefPubMed

35.

Ota N, Kato K, Iwano S, Ito S, Abe S, Fujita N, et al. Comparison of (1)(8)F-fluoride PET/CT, (1)(8)F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study. Br J Radiol. 2014;87:20130444. doi:10.1259/bjr.20130444.CrossRefPubMedPubMedCentral

36.

Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Turler A, et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2014;41:59–67. doi:10.1007/s00259-013-2532-6.CrossRefPubMed

37.

Even Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.PubMed

38.

Krger S, Buck A, Mottaghy F, Hasenkamp E, Pauls S, Schumann C, et al. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:1807–12.CrossRef

39.

Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med. 1999;40:1623–9.PubMed

40.

Iagaru A, Mittra E, Dick D, Gambhir S. Prospective Evaluation of (99m)Tc MDP Scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for Detection of Skeletal Metastases. Molecular imaging and biology. 2011.

41.

Yen RF, Chen CY, Cheng MF, Wu YW, Shiau YC, Wu K, et al. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Commun. 2010;31:637–45. doi:10.1097/MNM.0b013e3283399120.PubMed

42.

Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004;45:272–8.PubMed

43.

44.

Schirrmeister H, Glatting G, Hetzel J, Nussle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800–4.PubMed

45.

Hetzel M, Arslandemir C, Konig HH, Buck AK, Nussle K, Glatting G, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res. 2003;18:2206–14. doi:10.1359/jbmr.2003.18.12.2206.CrossRefPubMed

46.

Drubach LA. Clinical Utility of 18F NaF PET/CT in Benign and Malignant Disorders. Pet Clin. 2012;7:293–301.CrossRefPubMed

47.

Uchida K, Nakajima H, Miyazaki T, Yayama T, Kawahara H, Kobayashi S, et al. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study. J Nucl Med. 2009;50:1808–14. doi:10.2967/jnumed.109.062570.CrossRefPubMed

48.

Lim R, Fahey FH, Drubach LA, Connolly LP, Treves ST. Early experience with fluorine-18 sodium fluoride bone PET in young patients with back pain. J Pediatr Orthop. 2007;27:277–82. doi:10.1097/BPO.0b013e31803409ba.CrossRefPubMed

49.

Tan AL, Tanner SF, Waller ML, Hensor EM, Burns A, Jeavons AP, et al. High-resolution [18F]fluoride positron emission tomography of the distal interphalangeal joint in psoriatic arthritis—a bone-enthesis-nail complex. Rheumatology. 2013;52:898–904. doi:10.1093/rheumatology/kes384.CrossRefPubMed

50.

Strobel K, Fischer DR, Tamborrini G, Kyburz D, Stumpe KD, Hesselmann RG, et al. 18F-fluoride PET/CT for detection of sacroiliitis in ankylosing spondylitis. Eur J Nucl Med Mol Imaging. 2010;37:1760–5. doi:10.1007/s00259-010-1464-7.CrossRefPubMed

51.

Kobayashi N, Inaba Y, Tateishi U, Yukizawa Y, Ike H, Inoue T, et al. New application of 18F-fluoride PET for the detection of bone remodeling in early-stage osteoarthritis of the hip. Clin Nucl Med. 2013;38:e379–83. doi:10.1097/RLU.0b013e31828d30c0.CrossRefPubMed

52.

Dasa V, Adbel-Nabi H, Anders MJ, Mihalko WM. F-18 fluoride positron emission tomography of the hip for osteonecrosis. Clin Orthop Relat Res. 2008;466:1081–6. doi:10.1007/s11999-008-0219-2.CrossRefPubMedPubMedCentral

53.

Aratake M, Yoshifumi T, Takahashi A, Takeuchi R, Inoue T, Saito T. Evaluation of lesion in a spontaneous osteonecrosis of the knee using 18F-fluoride positron emission tomography. Knee Surg Sports Traumatol Arthrosc. 2009;17:53–9. doi:10.1007/s00167-008-0641-8.CrossRefPubMed

54.

Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008;14:2387–95. doi:10.1158/1078-0432.CCR-07-1430.CrossRefPubMed

55.

Wilde F, Steinhoff K, Frerich B, Schulz T, Winter K, Hemprich A, et al. Positron-emission tomography imaging in the diagnosis of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107:412–9. doi:10.1016/j.tripleo.2008.09.019.CrossRefPubMed

56.

Installe J, Nzeusseu A, Bol A, Depresseux G, Devogelaer JP, Lonneux M. (18)F-fluoride PET for monitoring therapeutic response in Paget’s disease of bone. J Nucl Med. 2005;46:1650–8.PubMed

57.

Fischer DR, Maquieira GJ, Espinosa N, Zanetti M, Hesselmann R, Johayem A, et al. Therapeutic impact of [(18)F]fluoride positron-emission tomography/computed tomography on patients with unclear foot pain. Skelet Radiol. 2010;39:987–97. doi:10.1007/s00256-010-0875-7.CrossRef

58.

Sterner T, Pink R, Freudenberg L, Jentzen T, Quitmann H, Bockisch A, et al. The role of [18F]fluoride positron emission tomography in the early detection of aseptic loosening of total knee arthroplasty. Int J Surg. 2007;5:99–104. doi:10.1016/j.ijsu.2006.05.002.CrossRefPubMed

59.

Temmerman OP, Raijmakers PG, Heyligers IC, Comans EF, Lubberink M, Teule GJ, et al. Bone metabolism after total hip revision surgery with impacted grafting: evaluation using H2 15O and [18F]fluoride PET; a pilot study. Mol Imaging Biol. 2008;10:288–93. doi:10.1007/s11307-008-0153-4.CrossRefPubMedPubMedCentral

60.

Slipman CW, Patel RK, Vresilovic EJ, Brautigam P, Mathies A, Adam LE, et al. Osseous stress reaction in a rower diagnosed with positron emission tomography (PET): a case report. Pain Phys. 2001;4:336–42.

61.

Berding G, Burchert W, van den Hoff J, Pytlik C, Neukam FW, Meyer GJ, et al. Evaluation of the incorporation of bone grafts used in maxillofacial surgery with [18F]fluoride ion and dynamic positron emission tomography. Eur J Nucl Med. 1995;22:1133–40.CrossRefPubMed

62.

Brenner W, Bohuslavizki KH, Eary JF. PET imaging of osteosarcoma. J Nucl Med. 2003;44:930–42.PubMed

63.

Drubach LA, Johnston PR, Newton AW, Perez-Rossello JM, Grant FD, Kleinman PK. Skeletal trauma in child abuse: detection with 18F-NaF PET. Radiology. 255:173–81. doi: 10.1148/radiol.09091368.

64.

Ovadia D, Metser U, Lievshitz G, Yaniv M, Wientroub S, Even-Sapir E. Back pain in adolescents: assessment with integrated 18F-fluoride positron-emission tomography-computed tomography. J Pediatr Orthop. 2007;27:90–3. doi:10.1097/01.bpo.0000242438.11682.10.CrossRefPubMed

65.

Laverick S, Bounds G, Wong WL. [18F]-fluoride positron emission tomography for imaging condylar hyperplasia. Br J Oral Maxillofac Surg. 2009;47:196–9. doi:10.1016/j.bjoms.2008.08.001.CrossRefPubMed

66.

Donohoe KJ, Henkin RE, Royal HD, Brown ML, Collier BD, O’Mara RE, et al. Procedure guideline for bone scintigraphy: 1.0. Society of Nuclear Medicine. J Nucl Med. 1996;37:1903–6.PubMed

67.

Treves ST, Parisi MT, Gelfand MJ. Pediatric radiopharmaceutical doses: new guidelines. Radiology. 261:347–9. doi: 10.1148/radiol.11110449.

68.

Blau M, Ganatra R, Bender MA. 18 F-fluoride for bone imaging. Semin Nucl Med. 1972;2:31–7.CrossRefPubMed

69.

Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Radiology. 1998;209:253–8.CrossRefPubMed

70.

Brunkhorst T, Boerner AR, Bergh S, Otto D, Gratz FW, Knapp WH. Pretherapeutic assessment of tumour metabolism using a dual tracer PET technique. Eur J Nucl Med Mol Imaging. 2002;29:1416. doi:10.1007/s00259-002-0964-5.CrossRefPubMed

71.

Iagaru A, Mittra E, Yaghoubi SS, Dick DW, Quon A, Goris ML, et al. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med. 2009;50:501–5. doi:10.2967/jnumed.108.058339.CrossRefPubMed

72.

Frost ML, Cook GJ, Blake GM, Marsden PK, Benatar NA, Fogelman I. A prospective study of risedronate on regional bone metabolism and blood flow at the lumbar spine measured by 18F-fluoride positron emission tomography. J Bone Miner Res. 2003;18:2215–22. doi:10.1359/jbmr.2003.18.12.2215.CrossRef

73.

Frost ML, Siddique M, Blake GM, Moore AE, Schleyer PJ, Dunn JT, et al. Differential effects of teriparatide on regional bone formation using (18)F-fluoride positron emission tomography. J Bone Miner Res. 26:1002–11. doi:10.1002/jbmr.305.

74.

Schiepers C, Nuyts J, Bormans G, Dequeker J, Bouillon R, Mortelmans L, et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med. 1997;38:1970–6.PubMed

75.

Cook GJ, Lodge MA, Marsden PK, Dynes A, Fogelman I. Non-invasive assessment of skeletal kinetics using fluorine-18 fluoride positron emission tomography: evaluation of image and population-derived arterial input functions. Eur J Nucl Med. 1999;26:1424–9.CrossRefPubMed

76.

Blake GM, Seddique M, Frost ML, Moore AE, Fogelman I. Quantitative PET imaging using 18F Sodium Fluoride in the assessment of metabolic bone disease and the monitoting of their response to therapy. Pet Clin. 2012;7:275–91.CrossRefPubMed

77.

Wootton R, Dore C. The single-passage extraction of 18F in rabbit bone. Clin Phys Physiol Meas. 1986;7:333–43.CrossRefPubMed

78.

Piert M, Zittel TT, Machulla HJ, Becker GA, Jahn M, Maier G, et al. Blood flow measurements with [(15)O]H2O and [18F]fluoride ion PET in porcine vertebrae. J Bone Miner Res. 1998;13:1328–36. doi:10.1359/jbmr.1998.13.8.1328.CrossRefPubMed

79.

Siddique M, Blake GM, Frost ML, Moore AE, Puri T, Marsden PK, et al. Estimation of regional bone metabolism from whole-body 18F-fluoride PET static images. Eur J Nucl Med Mol Imaging. 39:337–43. doi:10.1007/s00259-011-1966-y.

80.

Blake GM, Siddique M, Frost ML, Moore AE, Fogelman I. Radionuclide studies of bone metabolism: do bone uptake and bone plasma clearance provide equivalent measurements of bone turnover? Bone. 49:537–42. doi: 10.1016/j.bone.2011.05.031.

81.

Kawaguchi M, Tateishi U, Shizukuishi K, Suzuki A, Inoue T. 18F-fluoride uptake in bone metastasis: morphologic and metabolic analysis on integrated PET/CT. Ann Nucl Med. 2010;24:241–7. doi:10.1007/s12149-010-0363-0.CrossRefPubMed

82.

Vali R, Beheshti M, Waldenberger P, Fitz F, Haim S, Nader M, et al. Assessment of malignant and benighn bone lesions by static F-18 Fluoride PET-CT: additional value of SUV! J Nucl Med. 2008;49:150P.

83.

Cook Jr G, Parker C, Chua S, Johnson B, Aksnes AK, Lewington VJ. 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res. 2011;1:4. doi:10.1186/2191-219X-1-4.CrossRefPubMedPubMedCentral

84.

Tateishi U, Morita S, Taguri M, Shizukuishi K, Minamimoto R, Kawaguchi M, et al. A meta-analysis of (18)F-Fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med. 24:523–31. doi:10.1007/s12149-010-0393-7.

85.

Xia T, Alessio AM, De Man B, Manjeshwar R, Asma E, Kinahan PE. Ultra-low dose CT attenuation correction for PET/CT. Phys Med Biol. 57:309–28. doi:10.1088/0031-9155/57/2/309.

86.

Huang B, Law MW, Khong PL. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology. 2009;251:166–74. doi:10.1148/radiol.2511081300.CrossRefPubMed

87.

Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766–74. doi:10.1007/s00259-008-0788-z.CrossRefPubMed

88.

Radiation dose to patients from radiopharmaceuticals (addendum 3 to ICRP Publication 53) ICRP publication 106 approved by the Commission in October 2007. Ann ICRP 2008;38:1–197.

89.

Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53): ICRP publication 80, approved by the Commission in September 1997. Ann ICRP. 1998;28:1–126.

Title: 18F-NaF PET/CT: EANM procedure guidelines for bone imaging
Authors: M. Beheshti
F. M. Mottaghy
F. Payche
F. F. F. Behrendt
T. Van den Wyngaert
I. Fogelman
K. Strobel
M. Celli
S. Fanti
F. Giammarile
B. Krause
W. Langsteger
Publication date: 01-10-2015
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-015-3138-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

¹⁸F-NaF PET/CT: EANM procedure guidelines for bone imaging

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2015

Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?

iROLL: does 3-D radioguided occult lesion localization improve surgical management in early-stage breast cancer?

Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology

Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?

PET imaging of DNA damage using 89Zr-labelled anti-γH2AX-TAT immunoconjugates

Erratum to: First-in-human evaluation of a hybrid modality that allows combined radio- and (near-infrared) fluorescence tracing during surgery